Here is the latest shareholding Pattern of GLENMARK PHARMA. For more details, see the GLENMARK PHARMA financial fact sheet and GLENMARK PHARMA share price. For a sector overview, read our pharmaceuticals sector report.
No. of Mths Qtr. Ending |
3
Dec-22 |
3
Mar-23 |
3
Jun-23 |
3
Sep-23 |
3
Dec-23 |
3
Mar-24 |
3
Jun-24 |
3
Sep-24 |
||
---|---|---|---|---|---|---|---|---|---|---|
Indian Promoters | % | 46.65 | 46.65 | 46.65 | 46.65 | 46.65 | 46.64 | 46.65 | 46.65 | |
Foreign Promoters | % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Total Promoters | % | 46.65 | 46.65 | 46.65 | 46.65 | 46.65 | 46.64 | 46.65 | 46.65 | |
Mutual Funds | % | 5.64 | 5.43 | 5.36 | 7.30 | 8.59 | 10.55 | 10.92 | 11.41 | |
Financial institution/Banks/Insurance | % | 4.68 | 4.61 | 3.38 | 2.64 | 1.88 | 2.39 | 2.03 | 0.70 | |
Government | % | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | |
FII | % | 23.19 | 22.47 | 25.52 | 24.79 | 23.71 | 21.38 | 20.98 | 23.05 | |
Other | % | 0.38 | 0.35 | 0.37 | 0.38 | 0.45 | 0.42 | 0.97 | 1.10 | |
Total Institution | % | 33.93 | 32.90 | 34.67 | 35.15 | 34.67 | 34.78 | 34.94 | 36.30 | |
Bodies Corporate | % | 1.26 | 1.94 | 2.15 | 2.09 | 2.64 | 2.46 | 2.55 | 2.26 | |
Individuals | % | 16.72 | 16.90 | 15.20 | 14.84 | 14.78 | 14.83 | 14.58 | 13.60 | |
NRIs/OCBs | % | 0.95 | 1.11 | 0.95 | 0.90 | 0.90 | 0.92 | 0.93 | 0.87 | |
ADR/GDR | % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Others | % | 0.49 | 0.50 | 0.39 | 0.38 | 0.37 | 0.37 | 0.35 | 0.33 | |
Total Non-Institution | % | 19.42 | 20.45 | 18.69 | 18.21 | 18.69 | 18.58 | 18.41 | 17.06 | |
Total Public | % | 53.00 | 53.00 | 53.00 | 53.00 | 53.00 | 53.00 | 53.00 | 53.00 | |
Grand Total | % | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | |
Pledged Promoter Holding | % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Subscriber Feature |
More Pharmaceuticals Company Shareholding Pattern: CIPLA ZYDUS LIFESCIENCES DIVIS LABORATORIES SUN PHARMA DR. REDDYS LAB
Stocks in Asia traded within a narrow range after Donald Trump's tariff plan caused turbulence in emerging markets during the previous session